Key result
GRK5 was significantly overexpressed in renal fibrosis and promoted disease progression by acting as an upstream regulator of the HDAC5/Smad3 signaling pathway.
Why the study?
Renal fibrosis is a major cause of ESRD in CKD, but the role of GRK5 in its pathogenesis remains largely unknown.
GRK5 promotes renal fibrosis via the HDAC5/Smad3 signaling pathway, identifying it as a potential therapeutic target for chronic kidney disease.
GRK5 may drive renal fibrosis in CKD; hypothesis-generating for targeted inhibition pending validation.
Renal fibrosis is a common pathological feature of chronic kidney diseases (CKD), poses a significant burden in the aging population, and is a major cause of end-stage renal disease (ESRD). In this study, we investigated the role of G protein-coupled receptor kinases (GRKs) 5 in the pathogenesis of renal fibrosis. GRK5 is a serine/threonine kinase that regulates G protein-coupled receptor (GPCR) signaling. GRK5 has been shown to play a role in various diseases including cardiac disorders and cancer. However, the role of GRK5 in renal fibrosis remains largely unknown. Our finding revealed that GRK5 was significantly overexpressed in renal fibrosis. Specifically, GRK5 was transferred into the nucleus via its nuclear localization sequence to regulate histone deacetylases (HDAC) 5 expression under renal fibrosis. GRK5 acted as an upstream regulator of HDAC5/Smad3 signaling pathway. HDAC5 regulated and prevented the transcriptional activity of myocyte enhancer factor 2A (MEF2A) to repress the transcription of Smad7 which leading to the activation of Smad3. These findings first revealed that GRK5 may be a potential therapeutic target for the treatment of renal fibrosis. Inhibition of GRK5 activity may be a promising strategy to attenuate the progression of renal fibrosis.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2024) studied Renal fibrosis. GRK5 was evaluated on GRK5 expression and signaling pathway mechanisms. GRK5 was significantly overexpressed in renal fibrosis and promoted disease progression by acting as an upstream regulator of the HDAC5/Smad3 signaling pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: